Y-mAbs jumps on Q4 revenue beat

Y-mAbs Therapeutics

01/03/2024 13:28

** Shares of Y-mAbs Therapeutics  YMAB.O  rise 17.5% to
$19.63 premarket
    ** Co reports Q4 revenue of $23.4 mln on strong demand for
co's nerve tissue cancer therapy Danyelza, beating analysts'
average expectation of $20.95 mln - LSEG data
        ** Co forecasts annual revenue between $95 mln and $100
mln, the midpoint of which is above analysts' average estimate
of $96.27 mln
    ** Up to last close, stock up more than four-fold in the
last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))